A Prospective Multi-center Phase III Randomized Controlled Trial

Phase 3 Unknown 293 enrolled Sun Yat-sen University

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the PFS, ORR, OS and overall toxicity value（OTV）on advanced adenocarcinoma treated with nedaplatin or cisplatin combined with pemetrexed.

Timeline

Start: 2015-08
Primary completion: 2022-06
Completion: 2022-12

Publications

Results Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004 Jan 15;22(2):330-53. doi: 10.1200/JCO.2004.09.053. Epub 2003 Dec 22. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Cisplatin	Other / unclassified	25 mg/m2	—
Subject	Nedaplatin	Small molecule	90 mg/m2	—
Subject	Pemetrexed	Small molecule	500 mg/m2	—

A Prospective Multi-center Phase III Randomized Controlled Trial

Summary

Timeline

Publications

Drugs

Indications